Xiaoxue, a practitioner in the medical beauty industry, told Fujian Financial Reporter that the purchase price of Runbaiyan is around 500 yuan, Yiwan is around 1,000 yuan, and Qiao Yaden is around 3,500 to 4,000 yuan. . "On the one hand, the price of imported products is higher due to taxes and fees. For example, if Juvederm is taken from a Korean hospital, it only costs eight hundred yuan. On the other hand, imported hyaluronic acid does have a better shaping effect, Longer maintenance time and fewer allergic ingredients. Of course, some high-priced products also have added value such as outer packaging and hype.
Benefiting from the "appearance economy", the hyaluronic acid sunrise industry has high gross profit margins. , with many application scenarios, its potential is constantly being released. CITIC Securities Research predicts that by 2020, my country's hyaluronic acid beauty injection market demand will grow to 20 million to 30 million ml, becoming 100 billion. Yuan-level market. In the hyaluronic acid business, upstream manufacturers can obtain gross profit margins of more than 70%, while downstream hospitals and medical institutions depend on the specific pricing and positioning of hyaluronic acid products.
"Beauty. The industry is very profitable. From beauty salons to medical cosmetology, they all make money by selling technology. In addition, hyaluronic acid is a micro-plasticizing item. You can instantly become beautiful by doing it during your lunch break, so it is particularly popular and in high demand. In addition, if it is some informal medical institutions and American institutions with unqualified personnel, it will be more profitable.
Industry data shows that items such as hyaluronic acid fillers rank first in the sales of non-surgical medical beauty items in China. In the next step, medical cosmetology will usher in a wave of rapid growth in China. In the short term, hyaluronic acid still has promising business prospects, but due to its low threshold, market competition is bound to become more intense, and coupled with the high marketing costs of medicine and the United States, it may not become a long-term "cash cow."